154 related articles for article (PubMed ID: 31707279)
1. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA.
Du W; Qiu T; Liu H; Liu A; Wu Z; Sun X; Qin Y; Su W; Huang Z; Yun T; Jiao W
Heliyon; 2024 May; 10(9):e29605. PubMed ID: 38707478
[TBL] [Abstract][Full Text] [Related]
3. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of
Zhang Q; Tao X; Yuan P; Zhang Z; Ying J; Guo L; Li N; Wang S; Li J; Liu Y; Guo W; Zhao S; Wu N
Cancer Med; 2023 Nov; 12(22):20864-20877. PubMed ID: 37965789
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Tong B; Xu Y; Zhao J; Chen M; Zhong W; Xing J; Wang M
Thorac Cancer; 2018 May; 9(5):640-645. PubMed ID: 29582563
[TBL] [Abstract][Full Text] [Related]
6. Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis.
Gan T; An W; Long Y; Wang J; Zhang H; Liao M
Clin Transl Oncol; 2024 Apr; 26(4):991-1000. PubMed ID: 38030870
[TBL] [Abstract][Full Text] [Related]
7. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Shi Y; Au JS; Thongprasert S; Srinivasan S; Tsai CM; Khoa MT; Heeroma K; Itoh Y; Cornelio G; Yang PC
J Thorac Oncol; 2014 Feb; 9(2):154-62. PubMed ID: 24419411
[TBL] [Abstract][Full Text] [Related]
8. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Trulson I; Klawonn F; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
Bilgin B; Kuralay Y; Yucel S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):215. PubMed ID: 38668879
[TBL] [Abstract][Full Text] [Related]
11. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
[TBL] [Abstract][Full Text] [Related]
13. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.
Zhang Q; Zhu L; Zhang J
BMC Cancer; 2015 Mar; 15():88. PubMed ID: 25886585
[TBL] [Abstract][Full Text] [Related]
15. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
Bernicker EH; Xiao Y; Abraham A; Yang B; Croix DA; Redpath S; Engstrom-Melnyk J; Shah R; Madala J; Allen TC
Oncologist; 2021 Jun; 26(6):e1050-e1057. PubMed ID: 33823082
[TBL] [Abstract][Full Text] [Related]
16. New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract][Full Text] [Related]
17. Deep learning-radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients.
Kim S; Lim JH; Kim CH; Roh J; You S; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Heo J
Sci Rep; 2024 Jan; 14(1):922. PubMed ID: 38195717
[TBL] [Abstract][Full Text] [Related]
18. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
Chougule A; Prabhash K; Noronha V; Joshi A; Thavamani A; Chandrani P; Upadhyay P; Utture S; Desai S; Jambhekar N; Dutt A
PLoS One; 2013; 8(10):e76164. PubMed ID: 24124538
[TBL] [Abstract][Full Text] [Related]
19. The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.
Xiong W; Du H; Ding W; Sun J; Xu M; Guo X
Respir Res; 2020 Jul; 21(1):185. PubMed ID: 32677947
[TBL] [Abstract][Full Text] [Related]
20. Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.
Roberts TJ; Kesselheim AS; Avorn J
JAMA Netw Open; 2023 Jan; 6(1):e2252562. PubMed ID: 36696113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
